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We report on a 41 year-old man with late recurrence of non-seminomatous germ cell 
tumor (NSGCT), which was successfully treated with intensity-modulated radiation 
therapy (IMRT). For the residual retrocrural tumor invading 11th and 12th thoracic 
vertebra with an abnormal level of tumor marker (α-fetoprotein: 23.2 ng/ml) after 
salvage chemotherapy, chemotherapy could not be continued due to its neurotoxicity 
and surgery could not be performed due to the location. In this situation, IMRT 
achieved complete response of tumor marker. He remains in complete clinical remission 
after 3 years. The efficacy of radiotherapy, especially IMRT, for NSGCT is discussed. 
  
Mini-abstract 
We report on a 41 year-old man with late recurrence of non-seminomatous germ cell 
tumor, which was successfully treated with intensity-modulated radiation therapy. 
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 The prognosis for non-seminomatous germ cell tumor (NSGCT) of the testis has been 
dramatically improved with a treatment protocol of cisplatin-based chemotherapy 
followed by surgical resection of residual tumor [1]. However, a small proportion of 
patients subsequently suffered relapses, and patients with recurrence more than 2 
years since initial chemotherapy have been reported to have significantly poor response 
to salvage surgery or chemotherapy [2]. Although surgical treatment for remaining 
tumor after salvage chemotherapy can achieve prolonged survival [3], the tumors are 
occasionally unresectable. Meanwhile, although radiation therapy for NSGCT had been 
considered to have little effect for NSGCT [4], the irradiation technology has progressed 
dramatically for recent years. We herein report a case with late recurrence of NSGCT 




A 25 year-old patient underwent right inguinal orchitectomy for a testicular tumor in 
October 1991. A mixed germ cell tumor, containing components of embryonal carcinoma, 
yolk sac tumor and teratoma, was diagnosed. The serum levels of tumor markers were 
elevated prior to orchitectomy with 10254 ng/ml α-fetoprotein (AFP) and 376 mIL/ml 
human β-chorionic gonadotropin (β-HCG). Computerized tomography (CT) showed a 
huge retroperitoneal lymph node metastasis. Three cycles of chemotherapy containing 
cisplatin, cyclophosphamide, vinblastine, actinomycin D and bleomycin and following  
retroperitoneal lymph node dissection was performed. Pathological diagnosis for 
resected tumor was teratoma. He had regular follow-up with no evidence of tumor for 
the first 10 years, but had been lost to follow-up for the next 5 years. In September 2007, 
at the age of 41, he visited our clinic with a complaint of flank pain. CT findings showed 
a solitary 9 cm retrocrural mass invading 11th and 12th thoracic vertebras and 
surrounding the thoratic aorta. The serum levels of AFP and β-HCG were 2057 ng/ml 
and 5.2 mIL/ml, respectively. He received salvage chemotherapy with diagnosis of a late 
recurrence of non-seminomatous germ cell tumor. After one cycle of cisplatin and 
etoposide and two cycles of cisplatin and paclitaxel and ifosfamide, he suffered from 
severe chemotherapy-induced peripheral neuropathy which had been sustained at the 
level of grade 2. Additional two cycles of chemotherapy with alternative regimens 
containing irinotecan and nedaplatin worsened neuropathy to grade 3, indicating 
difficulty for further chemotherapy. At this point, AFP still showed an elevated level 
(23.2 ng/ml) and AFP-L3 fraction was also high (63.6%) although β-HCG returned to the 
normal value. Moreover, the residual retroperitoneal mass in positron emission 
tomography (PET) showed uptake of 18 F-deoxyglucose (FDG) (Fig.1). Although these 
data suggested viable tumor cells remaining, we judged curative surgery with the 
resection for the invaded vertebral body and aorta to be highly challenging and difficult 
to perform because of a high risk of severe paraplegia and lethal bleeding. 
We selected radiation therapy with a simultaneous integrated boost IMRT (SIB-IMRT) 
technique (Fig.2) to deliver enough doses to all targets including vertebral lesions while 
sparing the spinal cord and kidneys. The clinical target volume (CTV) definition was 
based on the PET/CT and MRI. The planning target volume (PTV) was created by 
adding an automatic isotropic 5-mm margin. Briefly, seven equidistant 6-MV beams 
(incident at angles of 50° ,80° ,150° ,180° ,210° ,280° ,310° ) were used, and 
intensity-modulated beams were delivered using a dynamic multileaf technique. A dose 
of 60 Gy was delivered to the FDG-PET positive lesions, while 54 Gy was prescribed to 
other PTV in 30 fractions simultaneously using SIB-IMRT technique. Dose-volume 
histogram analysis showed that the mean dose delivered to the PTV was 61.2 Gy. The 
maximal doses to the spinal cord and duodenum were 50.2Gy and 49.6Gy, respectively. 
The mean doses to the pancreas, left kidney and right kidney were 31.8Gy, 10.6 Gy and 
12.6 Gy, respectively, indicating within tolerance doses to those tissues.   
Acute toxicity, evaluated according to the Common Terminology Criteria for Adverse 
Events Version 3.0, was only grade 1 anorexia. There was no neurological adverse effect 
induced by the IMRT. AFP returned to the normal value, and AFP-L3 fraction also fell 
to an undetectable level two months after the radiotherapy. The patient has no signs of 
elevated serum markers and growth of the residual mass with negative PET 
examination (Fig.3) 3 years after the salvage radiation.  
 
Discussion 
 To our knowledge, this is the first report of NSGCT successfully treated by IMRT. The 
clinical course of this case suggested the possibility of curative radiation therapy for 
NSGCT despite previous reports showing poor response.  
Kersh, et al. showed that radiation therapy with a mean dose of 40 Gy was effective in 
patients with seminomas, but not in those with NSGCT [4]. However, no clinical study 
of radiation therapy for NSGCT with doses of more than 60 Gy, which is generally 
considered to be curative for solid tumors, has been reported. One previous case report 
showed that occult lumbar vertebral body metastasis of NSGCT was eradicated by 
radiation with a total dose of 61Gy [5], suggesting that dose escalation could be 
correlated with good outcome in NSGCT as well as prostate cancer [6]. Meanwhile, dose 
escalation is generally limited by severe complication resulting from damages to the 
surrounding organs. IMRT contributes not only to dose escalation to the target lesions 
but also to reduction in toxicity because it works to conform to the shape of the target 
lesions minimizing radiation dose to surrounding normal tissues. This suggests that 
IMRT could be a valuable tool for treating retroperitoneal tumors surrounded by 
important intraperitoneal organs. Actually, IMRT has been applied to less 
radio-sensitive tumors such as head and neck sarcoma or melanoma than NSGCTs 
through its advantages of local dose escalation and limited toxicity [7]. In our case, dose 
escalation by using IMRT could contribute to local control of the residual tumor.  
 The feature in our case was sole elevation of AFP.  This suggests the possibility that 
the residual tumor was teratoma which was more radiosensitive than other NSGCTs 
[4,8,9,10].  However, limitation in our case was no pathological evidence of the residual 
tumor because resection of the tumor was impossible.  Therefore, it remains to be 
elucidated whether radiotherapy have equivalent efficacy for patients with elevation of 
AFP.   
 In conclusion, for localized residual tumors after salvage chemotherapy, high dose 
salvage radiation therapy by using IMRT might be an alternative treatment option to 
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